<DOC>
	<DOCNO>NCT01040208</DOCNO>
	<brief_summary>The current trial explore safety flibanserin combination Selective Serotonin Reuptake Inhibitors Norepinephrine Serotonin Reuptake Inhibitors representative population woman depressive possible concurrent anxiety symptomatology .</brief_summary>
	<brief_title>12 Week Safety Trial Flibanserin Depressed Women Taking SSRI SNRI With Decreased Sexual Desire Distress</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Inclusion criterion : 1 . Women 1850 year age , postmenopausal Screen Visit 2 . Women mild/remitted depressive disorder score &lt; 11 Quick Inventory Depressive Symptoms Self Report &lt; 16 Beck Anxiety Inventory Screen/Baseline Visits 3 . Women decrease sexual desire distress present least 4 week Screen Visit determine Clinical Interview Female Sexual DysfunctionDepression Diagnostic Statistical Manual IVText Revision ( DSM IVTR ) 4 . Score 15 high Female Sexual Distress ScaleRevised Screen/Baseline Visits 5 . Score 9 low Changes Sexual Functioning QuestionnaireFemale desire/interest item Screen/Baseline Visits 6 . Patients must take Selective Serotonin Reuptake Inhibitor Norepinephrine Serotonin Reuptake Inhibitor 3 month stable dose least 2 month Screen Visit remain regimen trial 1 month trial completion 7 . Patients must treatment Female Sexual Dysfunction 2 month Screen Visit 8 . Patients must use medically accepted contraception method 9 . Patients must secure , stable , monogamous , heterosexual relationship least 12 month prior Screen Visit , accord Clinical Interview Female Sexual DysfunctionDepression Exclusion criterion : Conditions may interfere ability participate include , limited : 1 . Patients take Prohibited Medications within 30 day Baseline Visit 2 . Patients history drug dependence/abuse ( include alcohol ) within past year 3 . Patients history participation trial another investigational drug within 1 month prior Screen Visit , participation previous flibanserin study 4 . Women lifelong decrease sexual desire ( Hypoactive Sexual Desire Disorder ) , Female Sexual Arousal Disorder and/or Female Orgasmic Disorder , per DSM IVTR criteria 5 . Patients meet DSM IVTR criterion Sexual Aversion Disorder , SubstanceInduced Sexual Dysfunction Selective Serotonin Reuptake Inhibitor/Norepinephrine Serotonin Reuptake InhibitorInduced Sexual Dysfunction , Dyspareunia , Vaginismus , Gender Identity Disorder , Paraphilia , Sexual Dysfunction Due General Medical Condition 6 . Patients hysterectomy , post menopause stage ( i.e. , bilateral oophorectomy , chemically induced menopause ) 7 . Patients history pelvic inflammatory disease , urinary tract , vaginal infection/vaginitis , cervicitis , interstitial cystitis , vulvodynia , significant vaginal atrophy 4 week Screen Visit 8 . Patients breastfeed breastfed within 6 month prior Baseline Visit . 9 . Patients pregnant ( serum pregnancy test ) pregnant within 6 month prior Baseline Visit 10 . Patients current Depressive Disorder ( may concurrent mild Anxiety Disorder ) adequately control last 2 month and/or score &lt; 11 Quick Inventory Depressive Symptoms Self Report and/or score &lt; 16 Beck Anxiety Inventory Screen and/or Baseline Visits 11 . Patients history suicide attempt within last year current suicidal ideation . Investigator must assess history suicidality determine patient risk enter trial 12 . Patients history psychiatric disorder could impact sexual function , risk patient safety , may impact compliance . Axis I disorder ( except anxiety symptom disorder ) exclude . Axis II disorder allow 13 . Patients significant cardiac , neurologic , hepatic , renal , hematologic , respiratory , gastrointestinal , immunological , endocrine disease 14 . Patients history breast cancer cancer within last 5 year , noninvasive , previously resect skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>